ANNX U.S.: Nasdaq

    Annexon Inc.

    After Hours
    Last Updated: May 26, 2023 7:59 p.m. EDT Delayed quote

    $ 2.8000

    -0.04 -1.75%
    After Hours Volume: 55.57K
    Close Chg Chg %
    $2.8500 0.7500 35.71%
    Advanced Charting
    Volume: 6.48M 65 Day Avg: 742.16K
    873% vs Avg
    2.0900 Day Range 2.8500
    2.0700 52 Week Range 7.6500

    Partner Center

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ANNX Overview

    Key Data

    • Open $2.1000
    • Day Range 2.0900 - 2.8500
    • 52 Week Range 2.0700 - 7.6500
    • Market Cap $151.29M
    • Shares Outstanding 53.08M
    • Public Float 35.69M
    • Beta 0.93
    • Rev. per Employee N/A
    • P/E Ratio N/A
    • EPS -$2.4719
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 2.04M 05/15/23
    • % of Float Shorted 5.71%
    • Average Volume 742.16K


    5 Day
    • -51.69%
    1 Month
    • -46.28%
    3 Month
    • -47.12%
    • -44.87%
    1 Year
    • -12.84%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 8 Full Ratings

    Recent News

    Annexon downgraded to neutral from buy at BofA Securities

    Annexon Down 59% After Drug-Study Results, Analyst Comments

    Annexon Biosciences downgraded to neutral from overweight at J.P. Morgan

    Annexon Biosciences started at overweight with $33 stock price target at J.P. Morgan

    Annexon upsizes planned IPO to 12.5 million shares, narrows price range to $15 to $16 each

    Annexon Biosciences upsized its planned initial public offering on Thursday and narrowed the price range. The company is now planning to offer 12.5 million shares priced at $15 to $16 each, according to a regulatory filin...

    Annexon to offer 10 million shares in planned IPO priced at $14 to $16 each

    Annexon Biosciences set terms for its initial public offering on Monday, with plans to offer 10 million shares priced at $14 to $16 each. The company has applied to list on Nasdaq, under the ticker "ANNX." JP Morgan, BofA ...

    12 Health Care Stocks Moving In Monday's Intraday Session

    on Benzinga.com

    Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023

    on Benzinga.com

    Crude Oil Drops Sharply; Best Buy Earnings Top Expectations

    on Benzinga.com

    Analyst Expectations for Annexon's Future

    on Benzinga.com

    12 Health Care Stocks Moving In Thursday's Intraday Session

    on Benzinga.com

    Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    on Benzinga.com

    Nasdaq Surges 1.5%; NVIDIA Shares Jump Following Strong Q1 Results

    on Benzinga.com

    Why Shares of Annexon Are Plummeting Thursday

    on Motley Fool

    Why Annexon (ANNX) Stock Is Getting Hammered

    on Benzinga.com

    Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023

    on Benzinga.com

    Dow Drops 100 Points; US GDP Tops Estimates

    on Benzinga.com

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    on Benzinga.com

    Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study

    on Benzinga.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    on InvestorPlace.com

    Annexon Drops after Geographic Atrophy Candidate Disappoints

    on TipRanks.com

    BTIG Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)

    on TipRanks.com

    Analysts’ Top Healthcare Picks: Annexon Biosciences (ANNX), Aravive (ARAV)

    on TipRanks.com

    Analyst Ratings for Annexon

    on Benzinga.com

    The Latest Analyst Ratings for Annexon

    on Benzinga.com

    Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet

    The average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in ear...

    on Zacks.com

    Annexon Inc.

    Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.


    Name Chg % Market Cap
    Johnson & Johnson -0.04% $401.11B
    Roche Holding AG Akt 0.51% CHF235.25B
    Roche Holding AG 1.11% CHF235.25B
    AstraZeneca PLC 1.22% £182.64B
    AstraZeneca PLC ADR 1.20% $225.23B
    Novartis AG 0.41% CHF176.07B
    Sanofi S.A. -0.45% €124.64B
    GSK PLC 0.55% £56.68B
    Incyte Corp. -0.46% $13.96B
    Omeros Corp. 1.05% $363.15M